TP53 and colorectal cancer: Based on the results in the mouse system[91,92,135] and rhesus macaques [136], a phase I/II clinical study involving vaccination of end-stage colorectal cancer patients with a recombinant canarypox virus (ALVAC) encoding wild type p53 was performed[137].